Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Dimethylhexylamine (DMHA) has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Both raise sympathetic tone, and the cardiovascular effects add rather than cancel. Pre-workout formulas routinely combine them, which stacks heart rate and blood pressure responses in the same session. Anyone with a cardiovascular history or on stimulant medication has a real reason to avoid the combination.
The anhydrous form is the same molecule delivered in a fast-dissolving powder, so the peak plasma rise is sharper. Layering that peak onto an aliphatic amine stimulant concentrates the cardiovascular load into a short window. Dose stacking across two products is the common way people arrive at more than they intended.
Yohimbine blocks presynaptic alpha-2 receptors, which removes the brake on noradrenaline release. Adding it to an amine stimulant amplifies the sympathetic response rather than complementing it. Anxiety, palpitations and blood pressure spikes are the reported consequences of this stack.
Higenamine is a beta-adrenergic agonist that appears in the same product category. Its cardiovascular effects run in the same direction as an amine stimulant. Both are prohibited in competition under anti-doping rules, so the stack carries a sanction risk on top of the physiological one.
Theanine blunts the subjective jitteriness of caffeine in controlled studies, and formulators extend that logic to other stimulants. There is no published work testing theanine against this particular amine. Smoothing how something feels does not lower the cardiovascular load it is producing.
Melatonin signals the onset of biological night while an adrenergic stimulant does the opposite. Taken close together they work against each other, and the practical result is usually a poor night's sleep despite the melatonin. Human pharmacokinetics for this amine have not been published, so how late in the day a dose still interferes is not established.
Sedative botanicals are frequently taken to undo the sleep disruption a stimulant caused earlier in the day. The two pull in opposite directions rather than balancing out. Layering a sedative onto residual stimulant is a pattern worth naming rather than recommending.
St John's wort has weak monoamine oxidase activity in laboratory work and strongly induces CYP3A4. Combining a monoamine-releasing agent with anything touching monoamine oxidase is a recognised pharmacological hazard. This one belongs on a caution list rather than a stack list.
Rhodiola extracts inhibit monoamine oxidase in in vitro assays, though whether that translates to a meaningful effect at supplement doses in people is unresolved. Pairing it with a monoamine releaser is a theoretical concern that has not been quantified. Read it as mechanistic rather than clinical.
Alkalinising the urine reduces the ionised fraction of a basic amine in the renal tubule and slows its clearance, which extends exposure. This is the same principle that governs other basic sympathomimetics. Anyone dosing bicarbonate for training buffering should know it can prolong a stimulant's stay.
Beta-alanine appears in nearly every pre-workout that has carried this amine, and its paraesthesia is often mistaken for the stimulant taking effect. The two have no shared mechanism. Naming that confusion matters because people use the tingle to judge whether a dose landed.
Nothing specific on file for Dimethylhexylamine (DMHA). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.